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A 37-year-old heating, ventilation, and air-conditioning mechanic developed respiratory, muscu-
loskeletal, andcentral nervous system symptoms associatedwith avarietyofodorous environmen-
tal chemicals. Organic disease was not evident, but the patientwas distressed by these symptoms
and was at risk for becoming disabled bythem. His symptoms fit broadly into the condition rec-
ognized as multiple chemical sensitivity. Multiple chemical sensitivity is a diagnostic term for a
group ofsymptoms without demonstrated organic basis. The symptoms are characteristic ofdys-
fimction in multiple organ systems, theyincrease anddecreaseaccordingto exposuretolowlevels
ofchemical agents in the patient's environment, and they sometimes occur after a disinct envi-
ronmental change or insult such as an industrial accident or remodeling. Although traditional
medical organizations have not agreed on a definition for this syndrome, it is being increasingly
recognized and makes up an increasing percentage ofthe caseload at occupational and environ-
mental medicine clinics. Although there is often dispute about whether the symptoms have a
functional or organic basis, an informed approach to evaluation, diagnosis, andmanagement and
a careful assessment ofimpairment, disability, and workrelatedness are necessary. Carefil exclu-
sion oforganic causes is critical, and this should be followed by a judicious approach to coping
with symptoms. Keyword. chemicalexposure, multiple chemicalsensitivity, psychology. Environ
HealthPerspect108:377-381 (2000). [Online9 March2000]
http://ehpnetl.niehs.nih.govidoa/.0080p138p377-381kipen/abstracthtml
Case Presentation
A 37-year-old white male heating, ventila-
tion, and air-conditioning mechanic was
referred in 1992 for further evaluation of
headaches and chest tightness. He described
excellent health until a day in November
1991, when he removed a panel from an air-
conditioning unit and inhaled an unknown
gas or vapor, which produced face, nose, and
throat irritation. He developed a cough, sore
throat, and dizziness, but completed his day
at work. Irritation resolved over a long week-
end, but shortness ofbreath progressed until
he saw his primary care physician 5 days
later. The patient's physician determined
that he had symptoms ofbronchospasm and
a decreased forced vital capacity; he was
given bronchodilators and was told to take 2
weeks off from work. Most symptoms
resolved; however, after the patient returned
to work, he noted that exposure to a number
ofagents (including cigarette smoke, laundry
detergent, ammonia, air fresheners, cleaning
sprays, garden sprays, and paint fumes),
whether at home or work, gave him the
following immediate symptoms: a foul taste
in his mouth, gagging, eye irritation, chest
tightness, nonproductive cough, myalgias,
and arthralgias. After the exposures he noted
significant fatigue, a "spacy" feeling, and
headaches. Blood work, a repeat spirometry,
lung volumes, diffusing capacity, and arterial
blood gas were all normal. He purchased a
half-face organic vapor respirator that he
wore on the job, which resulted in a reduc-
tion in negative reactions. His symptoms
continued to improve despite stopping all
bronchodilator and other medications,
although milder systemic reactions persisted.
Past history. In 1990, while taking care
of his 5-year-old and 8-month-old children
when his wife was hospitalized, he developed
a transient anxiety disorder, which respond-
ed to anxiolytics. He had no atopic history
or history of respiratory disease. He was a
nonsmoker and used alcohol infrequently.
Examination. The patient was anxious
about his situation; he felt helpless to prevent
his sensitivity reactions and he felt that his
employer questioned the legitimacy of his
condition and his high level of medical
expenses. His physical examination and men-
tal status exam were normal. Pulmonary func-
tion tests were normal, with no significant
response to the bronchodilator. It was deter-
mined that formal neurobehavioral or psy-
chiatric testing was not indicated.
We recommended a methacholine chal-
lenge, which was declined by the patient; we
also recommended counseling to improve
his understanding ofand his response to his
symptoms. We informed the patient that we
did not feel he was disabled and that he
could continue to work using a respirator as
required. We informed his employer that he
was able to use a respirator, and should be
permitted to wear one on the job at his own
discretion.
Discussion
There is no widely accepted definition of
multiple chemical sensitivities (MCS)
because there is very little agreement on
what the symptoms represent. No definition
has yet been generally endorsed for clinical
use by a recognized body ofphysicians (1,2).
Nevertheless, there is a group(s) of patients
who present in a way (3,4) that leads us to
consider this topic; in fact, it is clinically
important and useful to recognize their dis-
tinctions from and overlaps with other diag-
nostic categories (3). Recognition, evaluation,
and treatment can be done from within a
perspective oftraditional allopathic, scientifi-
cally based practice.
MCS is most useful to distinguish per-
sons with medically unexplained symptoms
(e.g., fatigue, headache, concentration prob-
lems, and respiratory symptoms) when those
symptoms are attributed to and are triggered
by environmental exposures, as there is no
other specific diagnostic label to describe
such individuals. Many advocates ofthe con-
cept of chemical sensitivity, such as the
group of environmental physicians formerly
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called "clinical ecologists," espouse a broader
definition, which essentially includes all dis-
eases judged by a clinician to be caused or
aggravated bychemical exposure (5).
It is important to separate a considera-
tion of causes of this clinical picture from a
simple question ofwhether individuals exist
who have triggering of otherwise unex-
plained symptoms. Cullen's effort to define
MCS (6), primarily for research purposes, is
now the most widely used clinical definition
for this condition. Objective physiologic or
pathologic correlates have not been estab-
lished. This case definition, ifused as stated,
is intended to allow physicians to distinguish
MCS from other collections ofsimilar com-
monly experienced symptoms. It relies on
four salient characteristics:
* MCS is acquired in relation to some docu-
mentable environmental exposure that may
initially have produced a demonstrable
toxic effect. This aspect serves to exclude
patients with long-standing health prob-
lems who later attribute certain symptoms
to chemical exposure
* Symptoms involve more than one organ
system, and recur and abate in response to
predictable environmental stimuli. This
provides the salient feature of multiple
symptoms and multiple chemicals
* Symptoms are elicited by exposures to
chemicals that are demonstrable but very
low. The exposures eliciting symptoms
may be substantially below the typical
exposures known to cause toxic or irritant
health effects in humans and typically
involve chemicals ofwidelyvaried structur-
al classes and different mechanisms oftoxi-
cologic action
* The manifestations ofMCS are subjective.
There is no widely available (clinical) test
of organ system function that can explain
the symptoms, and there is no objective
evidence ofexplanatory organ system dam-
age ordysfunction (6).
An alternative and clinically useful
definition (2) took an operational approach:
anyone who endorsed at least three of four
items relecting lifestyle changes because of
chemicals could be considered to have MCS.
There is a reasonably high level ofagreement
between individuals who, upon clinical eval-
uation, meet the Cullen criteria (6) and those
who endorse three or four ofthese behavioral
items (8).
A major practical limitation of all avail-
able definitions of MCS is the subjectivity
and nonspecificity of the available informa-
tion regarding the predictable and demon-
strable attributes of the exposure-symptom
relationship. Whereas this relationship might
be most meaningfully established by double-
blinded and controlled exposure challenge
testing, it is usuallycharacterized solely on the
basis of the patient's report. Other proposed
definitions, and even other names, have been
published, but none has been validated, sub-
jected to substantial review, or achieved
widespread acknowledgment (9,10).
Classification and natural history.
Although there is no clear definition for
MCS, the available literature suggests useful
guides for individual patients, especially in
terms ofcomorbidity and severity. Akey con-
sideration is whether or not there is adiagnos-
able psychiatric condition. Higher rates of
diagnosable psychiatric conditions exist when
MCS subjects have been compared to con-
trols (11). Although rates are not necessarily
higher than for other groups ofpatients with
unexplained symptoms, rates ofdiagnosable
psychiatric conditions may reach 50%, some-
times 70%, which is far higher than in the
general population. There is also a high corre-
lation between the presence of psychiatric
comorbidity and whether the MCS is
reported to have a clear, defining onset, as in
the first Cullen criterion (lower psychiatric
comorbidity), or whether it developed gradu-
ally without a sudden overexposure incident
(higher psychiatric comorbidity) (8).
Patients frequently attribute changes in
severity of symptoms to control or lack of
exposure, but this has not been carefully
studied. One study suggests that self-report-
ed reduction of exposure is an important
determinant of well-being, but it was not
associated with reduction in actual reported
symptoms (12). MCS is not known to be
progressive in terms of measurable physical
dysfunction or development of medical
complications. Symptomatic reactions to
chemicals tend to persist, although some
individuals (such as the patient in this case)
learn to cope with such symptoms and
achieve relatively normal levels of function,
remaining employed.
Epidemiology. No population-based
studies have been published on the preva-
lence or incidence ofMCS according to the
definitions used here. Neverthess, the preva-
lence ofself-reported sensitivity to chemicals
(15%) and the prevalence of self-reported
receipt of a physician diagnosis of MCS
(6%) has now been reported in a rigorous
epidemiologic survey (4), confirming earlier
reports of high rates of chemical sensitivity
symptoms (13,14). Studies have document-
ed the presence ofchemical sensitivity symp-
toms in patients with fibromyalgia and
chronic fatigue syndrome (CFS) (16), Gulf
War Illness (15), as well as a high prevalence
ofCFS symptoms in those recruited as hav-
ing MCS (8,).
Etiologic theories. There are a multitude
of explanatory mechanisms, most based on
fairlylimited observations. Forsimplification,
these mechanisms may be grouped into four
categories: a) pathologic and toxicologic, b)
psychophysiologic, c) psychiatric, and a)
belief systems. In many individuals more
than one of these will seem to be operative;
in fact, the idea of complete distinctions
between psychophysiologic, pathologic, and
psychiatric mechanisms may at times be arti-
ficial. The relationship between MCS and
environmental chemical exposures has gener-
ally not been shown to meet benchmarks for
causality in terms ofepidemiologic data, dose
response, and established mechanisms (]7A.
Pathologic and toxicologic theories.
Theories oftoxicity or organ damage attrib-
utable to immunologic or otherdysfunctions
remain unsupported (11,14. In two studies
investigating the olfactory system in MCS
patients, it was determined that MCS sub-
jects do not detect odors at lower thresholds,
although they may respond more markedly
once odors are detected (11,18). The rela-
tionship of this finding to other reports of
nasal pathology and increased nasal resis-
tance is unexplored, and the pathologic find-
ings require confirmation with controlled
studies (18-21).
Psychophysiologicandpsychiatric theories.
Some investigators have proposed and have
begun to demonstrate that abehaviorally con-
ditioned response to odor could explain some
MCS cases (22-24). Such a severe chemical
exposure may act as an unconditioned stimu-
lus, producing one trial learning of a condi-
tioned psychologic response. For example,
exposure to glutaraldehyde, a known irritant,
is accompanied by an odor that could act as
the conditioned stimulus. The odor, as the
conditioned stimulus, then becomes associat-
ed with the irritative symptoms ofglutaralde-
hyde, the unconditioned stimulus. Thereafter,
the odor (or perhaps other similar odors),
paired with lower exposure concentrations,
could produce similar symptoms at levels of
exposure below a threshold for causing
mucosal irritation. On the other hand, an
odor may serve as a discriminative stimulus
rather than a conditioned stimulus. Some
recent data from our laboratory show a dose
response in MCS subjects for reported
trigeminal symptoms of nasal irritation fol-
lowing exposure to odorants (25). This is
inconsistent with the conditioned response
explanation shown above.
Many physical and emotional stressors
produce hyperventilation, as do a variety of
pulmonary, renal, cardiovascular, and other
disease states. Symptoms ofhyperventilation
can include some common symptoms of
MCS such as headache, dyspnea, palpita-
tions, tremor, panic, pain, and even seizure
activity (26). There are currently no data on
the association ofhyperventilation with MCS
symptoms, but this is one mechanism for
production ofsymptoms in multiple systems.
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Some intriguing case reports have associ-
ated organic solvents with panic attacks
(22,27,28). The substantial importance of
panic attacks in some cases of otherwise
unexplained symptoms has been recently
reviewed by Smoller et al. (29). For cases in
which one or more chemical odors trigger
either typical or limited panic attacks, the
designation of "odor-triggered panic attacks
or panic disorder" has been proposed (30).
Other theories ofcausation ofMCS include
more complex biologic mechanisms for the
conditioning model described above, relying
upon interaction between the olfactory, ner-
vous, and endocrine systems to explain odor-
triggered symptoms (17,31).
Beliefrystems. In some individuals, MCS
is characterized by a belief system (17); this
is consistent with the increasing concern of
the public regarding environmental pollu-
tion and health effects of exposure to man-
made chemicals (32,33). The mechanism by
which a set of beliefs might lead to symp-
toms is not clear, but it is easy to understand
how beliefs could affect attribution ifsymp-
toms were already present.
Diagnostic evaluation. In clinical prac-
tice there may be some confusion between
acute and chronic occupational or environ-
mental illnesses associated with objective
signs of disease and MCS, although some
patients mayhave both.
From a practical point ofview, differen-
tial diagnostic problems occur in two set-
tings. The first, as demonstrated with our
patient, is when early in the course of the
MCS, it is difficult to distinguish the syn-
drome from a defined occupational disease
such as occupational asthma. Later in the
course ofMCS, diagnosis may be complicat-
edbythe developmentofmore severe anxiety
and depression as a consequence ofhaving a
chronic condition, although this has not been
studied. Subsequent exaggeration ofpsychi-
atric symptomatology may lead such symp-
toms to overshadow chemically triggered
symptoms. We should be careful to avoid
inappropriate diagnosis of MCS in patients
who have well-defined toxic or allergic dis-
ease or irritant injury (e.g., asthma, lead
intoxication, or allergic alveolitis); an incor-
rect diagnosis could prevent patients from
receivingappropriatespecifictherapy.
Medical history and examination. The
keys to diagnosis and clinical management of
the individual presenting with suspected or
previously diagnosed MCS include a detailed
exposure history and a comprehensive med-
ical and psychosocial evaluation.
The baseline medical and psychiatric sta-
tus ofthe patient before development ofthe
presenting symptoms should be established.
The patient's medical history should include
current and previous illnesses, diagnostic
evaluations and treatments, and the possibil-
ity ofa long history ofunexplained physical
symptoms or excessive medical care. Patients
presenting with MCS may have long histo-
ries ofsimilar symptoms, but chemical attri-
bution maybe lacking (34).
The exposure history is fundamental for
an understanding ofpotential causal factors.
In addition to establishing the history of
symptoms triggered by exposures that are
tolerated by most people, it is important to
determine the circumstances ofthe initiating
exposure. The exdusion of traditional toxic
conditions, particularly irritant-induced
asthma and toxic encephalopathy, and the
consideration of the toxin-related anxiety
syndromes such as post-traumatic stress dis-
order and toxin-induced panic attacks must
be addressed. It must be determined whether
the exposure was substantially unusual, such
as an accident, the evacuation ofa building,
or another circumstance, raising the possibil-
ityofboth chemical damage and psychologic
trauma. The physician should estimate con-
centration and duration of exposures to
allow for the determination ofthe probabili-
ty that the symptoms are attributable to a
known toxic or irritant effect.
Physical examinations are performed
largelyto identify other medical conditions.
Diagnostic testing. The evaluating and
the treating physician must be wary about
excessive ordering as well as the misinterpre-
tation of diagnostic tests because these may
reinforce a detrimental pattern of illness
behavior (35). As with other types of unex-
plained symptoms, the primary physician
should function as gate keeper and should
order diagnostic tests primarily to identify
the presence of other environmental or
nonenvironmental illness in the differential.
There is currendy no test established to actu-
ally diagnose MCS. Short-term removal from
exposure to the environmental chemical of
concern mayhave diagnosticvalue; this short-
term removal may also have palliative value
while interventions that are more suitable for
long-term case management arearranged.
Many tests that have been asserted to
characterize MCS patients fall into thegeneral
realm of neurophysiology or neuroimaging.
Although no test of central nervous system
effects has been validated to confirm the pres-
ence of MCS (36), preliminary information
indicates that there maybestatisticallysignifi-
cant but notdinicallyvisable changes in brain
single photon emission computed tomogra-
phy (SPECT) images in individuals with
MCS ascompared to controls (37.
There is awidespread assertion that MCS
could be characterized by abnormalities of
immune system activation, lymphocyte sub-
types, and autoantibodies, which has been
studied in a limited number of controlled
trials. No form of immunologic testing has
been shown to effectively diagnose either
exposure to specific chemicals or illness due
to exposure in patientswith MCS (11).
Neuropsychologic testing is dependent
on patient cooperation and may be useful to
rule out other conditions in the differential
diagnosis. At present, neuropsychologic test-
ing does not reveal consistent or specific
findings in MCS patients that can be used
for diagnosis (8,38).
Definitive research on controlled chal-
lenge procedures using appropriate controls
is necessary before these procedures can be
recommended as tools for diagnosis (39-41).
Psychiatri evaluation. Psychiatric evalua-
tion may be appropriate for some patients
diagnosed with MCS, given the high preva-
lence of coexisting or preexisting psychiatric
disorders in these patients. Unfortunately,
manypatients given a diagnosis ofMCS resist
the idea that psychologic factors mayplayany
etiologic role at all in their distress; however,
this should not necessarily be interpreted that
the patient has a primary psychiatric illness.
The stigma placed on psychiatric disorders in
our society probably plays a major role in the
tendency to somatize. The adamant rejection
ofpsychologic factors in symptom formation
and expression byMCS patients is a challenge
for the physician, who must establish a work-
able strategy for approaching this issue that is
both sensitive to the patient's feelings and
effective in exploring possible emotional con-
tributors to thesyndrome (35). Forpsychiatric
evaluation to be most useful, it is necessary to
ensure that the clinician is familiar with the
subde nature of the toxicologic controversies
inMCS, asdiscussed above.
Clinical management. Very little is
known about the proper treatment ofMCS.
No therapy has been subjected to controlled
clinical trials to confirm short- or long-term
efficacy with these patients. Approaches to
treatment have paralleled etiologic theories,
and these have recently been reviewed (42).
Clinical ecologists and other practitioners
who believe that MCS is attributable to
immune dysfunction caused by elevated
body burdens of xenobiotics champion
avoidance ofchemical exposure, dietary sup-
plements, antioxidants, chelation therapies,
and the use of saunas (17,42,43). Many
patients do a great deal of independent
research about their conditions, and some
find support (including information and
misinformation) from self-help groups,
manyofwhich are on the Internet.
Practitioners who have a more psycholog-
ic view ofMCS have tried to apply pharma-
cologic and behavioral techniques (44). We
have often not found it helpful to directly
confront or debate whether chemicals could
or could not cause the patient's symptoms.
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Rather, as for any organic illness with a
behavioral component (e.g., heart disease),
we prefer to focus on coping strategies that
will improve the quality oflife and prevent
disability. Specifically, we work collabora-
tively with the patient to develop prudent
avoidance ofthose substances that cause the
most symptoms, and practical guidance
(e.g., ventilation, work breaks) to minimize
exposure when the patient needs to work or
function. Although radical avoidance is
inimical to enhancement of function at
work, the ability to use judicious avoidance
for control of regular and severe symptoms
may foster a therapeutic relationship.
Balancing the benefits ofanyavoidance mea-
sures with the potential risks of a spiraling
pattern ofprogressively severe environmental
restrictions and loss of employment is the
ultimate challenge of the MCS patient who
is still employed.
We also work with patients to identify
symptoms associated with fear or anxiety
about exposure. We then use relaxation
methods with or without biofeedback to
address the anxiety responses. Overall, treat-
ment is behavioral in nature, making use of
both cognitive behavioral and physical
relaxation techniques. Once litigation or a
worker's compensation claim has arisen, the
prognosis for behavioral approaches to treat-
ment is less optimistic. An approach to
thinking through litigation issues according
to the magnitude of the initiating stimulus
has been previously outlined (44).
Hyperventilation should be identified
and approached through breathing control,
stress management, and education. More
severe symptoms of depression or anxiety
should be medically managed with psy-
chotropics. Based on our experience, if psy-
chiatric medications are used, they must be
given at very low doses and then titrated up
to give these patients time to adjust to
potential side effects, which are anecdotally
reported to be more problematic in these
individuals and others with medically unex-
plained physical symptoms (48).
Cognitive behavioral therapy for medical-
ly unexplained symptoms, not specifically
including MCS, has been shown to be effec-
tive in two randomized trials, with a return-
to-work rate of up to 70% in one study
(46,44. Guglielmi et al. (48) identified three
MCS patients who met criteria for simple
phobia and who were, at least initially,
successfully treated by an intensive desensiti-
zation program consisting of biofeedback-
assisted relaxation training, in vivo exposure
to offending chemicals, and cognitive restruc-
turingprocedures.
Odors and exposure to volatile organic
compounds in the workplace and home,
which are perceived as irritating or noxious
by the symptomatic person, should be
reduced and controlled as much as possible.
Conclusions
Although it is often disputed whether the
symptoms of MCS have a functional or
organic basis, it is necessary to have an
informed approach to evaluation, diagnosis,
and management and a careful assessment of
impairment, disability, and work-related-
ness. It is optimal to have an integrated med-
ical and psychologic approach with careful
exclusion of organic causes, followed by a
judicious approach to coping. Those patients
who, after supportive counseling, continue
to deny that stress or psychologic factors
may play any role at all in their symptoms
probably cannot be helped by any of the
above behaviorally based therapies. The
patient who we described sought counseling
at another facility near his home and
remained at his job, although various
sensitivity reactions continue.
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